<DOC>
	<DOCNO>NCT00889889</DOCNO>
	<brief_summary>Immunogenicity safety cell-derived influenza vaccine adult age &gt; = 18 &lt; = 64 year , plus revaccination</brief_summary>
	<brief_title>Immunogenicity Safety Cell-derived Influenza Vaccine Adults Aged &gt; = 18 &lt; = 64 , Plus Revaccination</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Willing able give inform consent able adhere protocol require study procedure . 2 . Men woman age &gt; = 18 &lt; = 64 year . 3 . Being good health judge medical history , physical examination clinical judgment investigator . Exclusion Criteria 1 . Known allergic constituent vaccine . 2 . A serious adverse reaction previous ( influenza ) vaccination . Presence significant condition may prohibit inclusion determine investigator . 3 . Having receive vaccination influenza lab confirm influenza within previous six month study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Phase II</keyword>
	<keyword>Placebo-controlled</keyword>
</DOC>